文献速递疼痛医学

氯胺酮与镁剂治疗难治性神经病理性疼痛:随机双盲交叉试验

Ketamine and Magnesium for Refractory Neuropathic Pain: A Randomized, Double-blind, Crossover Trial.
PubMed 文献 · Anesthesiology · 2020-01-01

该随机双盲交叉安慰剂对照试验纳入20例神经病理性疼痛患者,比较氯胺酮、氯胺酮联合硫酸镁与安慰剂输注后35天内每日疼痛强度曲线下面积。结果显示三组间无显著差异,氯胺酮未在5周时提供镇痛或认知情绪获益,联合镁剂也无附加镇痛效应。

要点

  • 氯胺酮0.5 mg/kg输注未显著改善神经病理性疼痛35天疼痛曲线下面积。
  • 氯胺酮联合硫酸镁3g与单独氯胺酮或安慰剂相比无附加镇痛效应。
  • 三组情绪、睡眠及生活质量指标均无显著差异。

核心结论

  • 该试验结果驳斥了氯胺酮在5周时提供镇痛和认知情绪获益的假设。
  • 氯胺酮联合镁剂未显示任何附加镇痛效应。

研究设计与样本

  • 随机、双盲、交叉、安慰剂对照研究(NCT02467517),纳入20例神经病理性疼痛患者。
  • 每例患者每35天接受一次随机顺序输注:氯胺酮0.5 mg/kg/安慰剂、氯胺酮0.5 mg/kg/硫酸镁3g或安慰剂/安慰剂。
  • 主要终点为输注后35天内每日疼痛强度曲线下面积。

主要发现

  • 35天内每日疼痛强度三组间无显著差异(平均曲线下面积:氯胺酮185±100、氯胺酮/镁196±92、安慰剂187±90疼痛评分-天,P=0.296)。
  • 主要终点效应量:氯胺酮 vs 安慰剂 -0.2(95%CI [-0.6 to 0.3];P=0.425);安慰剂 vs 氯胺酮/镁 0.2(95%CI [-0.3 to 0.6];P=0.445);氯胺酮 vs 氯胺酮/镁 -0.4(95%CI [-0.8 to 0.1];P=0.119)。
  • 情绪、睡眠和生活质量测量无显著差异。
  • 安慰剂、氯胺酮和氯胺酮/镁输注期间,分别有10%、20%和35%的患者报告至少一次不良事件。

临床怎么用

  • 对于难治性神经病理性疼痛,单次静脉氯胺酮0.5 mg/kg或联合硫酸镁3g不应期望在5周时获得显著镇痛或认知情绪获益。

局限性

  • 样本量较小(n=20)。
  • 单次输注设计,未评估重复给药或不同剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ketamine is often used for the management of refractory chronic pain. There is, however, a paucity of trials exploring its analgesic effect several weeks after intravenous administration or in association with magnesium. The authors hypothesized that ketamine in neuropathic pain may provide pain relief and cognitive-emotional benefit versus placebo and that a combination with magnesium may have an additive effect for 5 weeks. METHODS: A randomized, double-blind, crossover, placebo-controlled study (NCT02467517) included 20 patients with neuropathic pain. Each ketamine-naïve patient received one infusion every 35 days in a random order: ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulfate (3g) or placebo/placebo.The primary endpoint was the area under the curve of daily pain intensity for a period of 35 days after infusion. Secondary endpoints included pain (at 7, 15, 21 and 28 days) and health-related, emotional, sleep, and quality of life questionnaires. RESULTS: Daily pain intensity was not significantly different between the three groups (n = 20) over 35 days (mean area under the curve = 185 ± 100, 196 ± 92, and 187 ± 90 pain score-days for ketamine, ketamine/magnesium, and placebo, respectively, P = 0.296). The effect size of the main endpoint was -0.2 (95% CI [-0.6 to 0.3]; P = 0.425) for ketamine versus placebo, 0.2 (95% CI [-0.3 to 0.6]; P = 0.445) for placebo versus ketamine/magnesium and -0.4 (95% CI [-0.8 to 0.1]; P = 0.119) for ketamine versus ketamine/magnesium. There were no significant differences in emotional, sleep, and quality of life measures. During placebo, ketamine, and ketamine/magnesium infusions, 10%, 20%, and 35% of patients respectively reported at least one adverse event. CONCLUSIONS: The results of this trial in neuropathic pain refuted the hypothesis that ketamine provided pain relief at 5 weeks and cognitive-emotional benefit versus placebo and that a combination with magnesium had any additional analgesic effect.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Pickering G, Pereira B, Morel V, et al. Ketamine and Magnesium for Refractory Neuropathic Pain: A Randomized, Double-blind, Crossover Trial. Anesthesiology. 2020. PMID: 32384291. doi:10.1097/ALN.0000000000003345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。